When great scientific minds unite, medicine advances

Meet the Scientific Advisory Board

Professor Ferid Murad, MD, PhD, was a Nobel Laureate and Professor of Medicine at Stanford University and Senior Research Advisor at the Palo Alto Institute for Research. He previously served as Chief of Medicine at Stanford’s Palo Alto Veterans Hospital, and Associate and Interim Chairman of Stanford’s Department of Medicine.

Evren Alici, MD, PhD, is Associate Professor and Leader of the Cell and Gene Therapy Group at the Center for Hematology and Regenerative Medicine, Department of Medicine, at the Karolinska Institutet. He has also served as Professor of Surgery at the College of Allopathic Medicine, Nova Southeastern University, having previously worked as an orthopaedic surgeon. Evren remains a Consulting Senior Surgeon at three leading university hospitals across the world.

Jean-Pierre Bizzari, MD, is an experienced biotechnology executive and scientist. Having trained as an oncologist in France and Canada, he joined the pharmaceutical industry in 1983 as Head of the Oncology at the Institut de Recherches Internationales SERVIER (France), and subsequently served as Vice President of Clinical Oncology at Rhone-Poulenc Rorer. He was later responsible for the Oncology Clinical Development at Aventis as Vice President.

Farzin Farzaneh, PhD, FRCPath, FRSB, is Chief Scientific Officer of ViroCell Biologics and serves as a member of the Board of Directors. He is also Chair of Molecular Medicine at King’s College London and Trans-campus Professor of Molecular Medicine at Technical University of Dresden, Germany.

One of the most highly regarded international Medical Oncologists of his generation, Dr. Harper has earned a distinguished service record in both the public and private sectors. In 1980 as General Physician & Medical Oncologist, he founded the Oncology Department at Guy's and St Thomas' NHS Foundation Trust, a leading global teaching hospital. He was responsible for funding its rise to a global cancer treatment leadership position through research and ground-breaking patient care.  

Professor Mark Lowdell, PhD, FRCPath, FRSB, is Senior Manufacturing Advisor and member of the Scientific Advisory Board of ViroCell Biologics. He is also the Professor of Cell & Tissue Therapy at University College London and Director of the Centre for Cell, Gene & Tissue Therapeutics / Honorary Consultant Immunologist at Royal Free Hospital (RFH) London.

Paul G. Richardson, MD, is the RJ Corman Professor of Medicine at Harvard Medical School, and Clinical Program Leader and Director of Clinical Research of the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute (DFCI) / Harvard Cancer Center. Dr. Richardson led the development of several first-generation novel drugs for the treatment of Multiple Myeloma (MM).